Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, entered a long-term agreement with Vertex Pharmaceuticals to perform analytical release testing services on the first CRISPR/Cas9 genome-edited cell therapy, CASGEVY.    CASGEVY (exagamglogene autotemcel or exa-cel) received FDA approval for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises.   The companies have worked together for several years to...